Real-world characterisation of severe asthma in Greece: results from the Greek Severe Asthma Registry.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fouka Evangelia, Kallieri Maria, Avarlis Pantelis, Bartziokas Konstantinos, Dimakou Katerina, Florou Aggeliki, Gaki Eleni, Georgatou Niki, Katsaounou Paraskevi, Katsoulis Konstantinos, Kostikas Konstantinos, Kotsiou Ourania, Latsios Dimitrios, Markatos Miltiadis, Michailopoulos Pavlos, Papakosta Despoina, Papapetrou Dimosthenis, Porpodis Konstantinos, Rovina Nikoletta, Sigala Ioanna, Siopi Dimitra, Solakis Athanasios, Steiropoulos Paschalis, Tzanakis Nikolaos, Tzortzaki Eleni, Vittorakis Stylianos, Zervas Eleftherios, Bakakos Petros, Loukides Stelios, Samitas Konstantinos
Аннотация
METHODS: We analysed data cross-sectionally from 619 adult patients (median age: 56 years; 61.1% female) with severe asthma, recruited across 13 specialised hospital centres and 11 private respiratory practices between March 2018 and November 2021. Patients were stratified by age of asthma onset, biologic therapy use and maintenance oral corticosteroid (mOCS) dependence. Clinical, inflammatory and treatment characteristics were assessed, alongside exacerbation predictors.
RESULTS: The study population exhibited substantial disease burden, with 434 patients (70.1%) experiencing ≥1 exacerbation and 149 (24.1%) requiring hospitalisation in the prior year. Late-onset asthma (60.7%) was associated with a faster progression to severe disease, higher exacerbation risk (79.8% versus 69.5%, p=0.004), and more frequent cardiometabolic comorbidities versus early-onset asthma. Despite better asthma control (Asthma Control Test ≥20: 61.8% versus 50.5%, p=0.012), biologically treated patients (57%) had more severe disease, including lower forced expiratory volume in 1 s (FEV1) % predicted (73% versus 81%, p<0.001). Patients receiving mOCS (18.9%) exhibited poorer asthma control, higher exacerbation rates and more frequent corticosteroid-related comorbidities. In multivariable models, elevated blood eosinophil count (incidence rate ratio: 1.044 per 100 cells per μL) and reduced FEV1% (odds ratio: 0.97 per 1% increase) were independent predictors of exacerbations.
CONCLUSIONS: This study highlights the phenotypic heterogeneity of severe asthma in Greece and reveals region-specific treatment patterns and unmet clinical needs despite access to advanced therapies. These real-world findings may guide national asthma care strategies and contribute to European initiatives aimed at optimising asthma management.